{"id":39386,"date":"2017-06-02T07:02:30","date_gmt":"2017-06-02T11:02:30","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=39386"},"modified":"2017-06-02T02:30:15","modified_gmt":"2017-06-02T06:30:15","slug":"good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386","title":{"rendered":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Xenetic Biosciences Inc (NASDAQ:XBIO),<\/strong> which happens to be one of the top and trusted clinical-stage biopharmaceutical companies globally focusing on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, has today broken its silence on the most awaited news.<\/p>\n<p style=\"text-align: justify;\">It has made it pretty clear for all the concerned parties that indeed it has received the expected update in line with the Phase 1\/2 clinical study which was reportedly conducted by its partner Shire, evaluating SHP656 (\u201cPSA-recombinant Factor VIII\u201d, \u201cPSA-rFVIII\u201d), and sources indicate that it is being manufactured as a long-acting therapeutic that will significantly aid in the treatment of hemophilia A.<\/p>\n<p style=\"text-align: justify;\">As a matter of fact, it is expected to utilize Xenetic&#8217;s PolyXen\u2122 platform technology that will facilitate the conjugation of polysialic acid to therapeutic blood-clotting factors.<\/p>\n<p style=\"text-align: justify;\">Some of the close sources indicate that the Phase 1\/2 study elaborately demonstrated SHP656\u2019s efficacy and this was termed a great sign by some top experts.<\/p>\n<p style=\"text-align: justify;\">Xenetic\u2019s Chief Executive Officer, M. Scott Maguire in a press briefing said, &#8220;Despite not achieving the principal objective of once-weekly dosing in this Phase 1\/2 study, our PolyXen technology clearly works as a platform to successfully extend the circulating half-life of rFVIII with no drug-related serious adverse events.<\/p>\n<p style=\"text-align: justify;\">He proceeded, \u201cIncluding our own studies with a polysialylated erythropoietin (\u201cPSA-EPO\u201d, \u201cErepoXen\u00ae\u201d) candidate, this is the second instance in which PolyXen has been demonstrated, in a human clinical trial setting, to confer extended half-life to a biotherapeutic, while maintaining pharmacological activity and a favorable safety and tolerability profile.\u201d<\/p>\n<p style=\"text-align: justify;\">Xenetic Biosciences Inc, just like the rest of the top companies has had its affair share of challenges in business, but one thing that is for sure is that it has remained vigilant in its business undertakings.<\/p>\n<p style=\"text-align: justify;\">Having tried out various strategies, some of which ended up in futility, most of its top officials firmly believe that the company is headed to the right direction and that it will see to it that patients across the globe access top notch solutions. A lot of resources are being directed into research, but they hope it pays off in the long run.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xenetic Biosciences Inc (NASDAQ:XBIO), which happens to be one of the top and trusted clinical-stage biopharmaceutical companies globally focusing on the discovery, research and development [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":39395,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12686,12685,12684],"stock_ticker":[],"class_list":["post-39386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqxbio","tag-xenetic-biosciences-inc","tag-xenetic-biosciences-inc-nasdaqxbio","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Xenetic Biosciences Inc (NASDAQ:XBIO), which happens to be one of the top and trusted clinical-stage biopharmaceutical companies globally focusing on the discovery, research and development [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-02T11:02:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"259\" \/>\n\t<meta property=\"og:image:height\" content=\"194\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study\",\"datePublished\":\"2017-06-02T11:02:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg\",\"keywords\":[\"NASDAQ:XBIO\",\"Xenetic Biosciences Inc\",\"Xenetic Biosciences Inc (NASDAQ:XBIO)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\",\"name\":\"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg\",\"datePublished\":\"2017-06-02T11:02:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg\",\"width\":259,\"height\":194},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386","og_locale":"en_US","og_type":"article","og_title":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR","og_description":"Xenetic Biosciences Inc (NASDAQ:XBIO), which happens to be one of the top and trusted clinical-stage biopharmaceutical companies globally focusing on the discovery, research and development [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-06-02T11:02:30+00:00","og_image":[{"width":259,"height":194,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study","datePublished":"2017-06-02T11:02:30+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg","keywords":["NASDAQ:XBIO","Xenetic Biosciences Inc","Xenetic Biosciences Inc (NASDAQ:XBIO)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386","url":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386","name":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg","datePublished":"2017-06-02T11:02:30+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/06\/39394-images__6_.jpeg","width":259,"height":194},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/good-news-for-hemophilia-a-patients-after-xenetic-biosciences-inc-nasdaqxbio-receives-program-update-from-partner-shires-phase-12-study-39386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Good News For Hemophilia A Patients After Xenetic Biosciences Inc (NASDAQ:XBIO) Receives Program Update From Partner Shire\u2019s Phase 1\/2 Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=39386"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/39395"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=39386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=39386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=39386"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=39386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}